MCID: GST049
MIFTS: 60

Gastrointestinal System Cancer

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastrointestinal System Cancer

MalaCards integrated aliases for Gastrointestinal System Cancer:

Name: Gastrointestinal System Cancer 12 14
Digestive System Neoplasms 41 69
Gastrointestinal Neoplasms 41 69
Malignant Neoplasm of Gastrointestinal Tract 69
Neoplasm of the Gastrointestinal Tract 28
Gastrointestinal Tract Cancer 12
Cancer of Digestive System 69
Digestive System Cancer 12
Gi Tumor 12

Classifications:



Summaries for Gastrointestinal System Cancer

Disease Ontology : 12 An organ system cancer located in gastrointestinal tract that is manifested in organs of the gastrointestinal system.

MalaCards based summary : Gastrointestinal System Cancer, also known as digestive system neoplasms, is related to gastrointestinal stromal tumor and pharynx cancer, and has symptoms including signs and symptoms, digestive An important gene associated with Gastrointestinal System Cancer is TLR9 (Toll Like Receptor 9), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs GastroMARK and Gleevec have been mentioned in the context of this disorder. Affiliated tissues include gastrointestinal tract, lung and liver, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Gastrointestinal System Cancer

Diseases in the Gastrointestinal System Cancer family:

Gastrointestinal System Benign Neoplasm

Diseases related to Gastrointestinal System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal stromal tumor 32.5 AKT1 CCND1 KIT TP53 VEGFA
2 pharynx cancer 32.3 AKT1 AREG CCND1 CDH1 EGFR TP53
3 oral cavity cancer 32.3 AREG EGFR VEGFA
4 esophageal cancer 32.0 AKT1 CCND1 CDH1 CEACAM5 CTNNB1 EGFR
5 gastric cancer 31.7 AFP AKT1 AREG CCND1 CDH1 CEACAM5
6 pancreatic cancer 30.2 AKT1 AREG CCND1 CDH1 CEACAM5 CTNNB1
7 neonatal inflammatory skin and bowel disease 10.9 ADAM17 EGFR
8 mature teratoma 10.9 AFP KRAS TP53
9 nasal cavity adenocarcinoma 10.9 HRAS KRAS TP53
10 sigmoid neoplasm 10.9 CEACAM5 HRAS KRAS
11 paronychia 10.8 EGFR HRAS KRAS
12 mucoepidermoid esophageal carcinoma 10.8 CEACAM5 TP53 WWOX
13 pulmonary blastoma 10.8 EGFR KRAS TP53
14 apocrine adenoma 10.8 CEACAM5 HRAS KRAS
15 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.8 CTNNB1 KRAS TP53
16 anal squamous cell carcinoma 10.8 AKT1 MLH1 TP53
17 gastrointestinal neuroendocrine tumor 10.8
18 gastrointestinal carcinoma 10.8
19 liver sarcoma 10.8 ADAM17 AFP CEACAM5
20 acneiform dermatitis 10.8 EGFR HRAS KRAS
21 biliary tract neoplasm 10.8 HRAS KRAS TP53
22 ethmoid sinus cancer 10.8 CCND1 EGFR HRAS
23 liver angiosarcoma 10.8 HRAS KRAS TP53
24 ethmoid sinus adenocarcinoma 10.8 CCND1 EGFR HRAS
25 atypical polypoid adenomyoma 10.8 CTNNB1 MLH1 MSH2
26 pleomorphic carcinoma 10.8 EGFR KIT TP53
27 mixed cell type cancer 10.8 HRAS KIT KRAS TP53
28 esophageal adenosquamous carcinoma 10.8 CDH1 CEACAM5 WWOX
29 esophagus squamous cell carcinoma 10.8 CCND1 CDH1 WWOX
30 adenosquamous cell lung carcinoma 10.8 EGFR HRAS KRAS
31 exanthem 10.8 EGFR HRAS KRAS TLR9
32 ovary serous adenocarcinoma 10.8 CEACAM5 HRAS KRAS
33 esophageal basaloid squamous cell carcinoma 10.8 CTNNB1 EGFR TP53 WWOX
34 lung adenoid cystic carcinoma 10.8 EGFR HRAS KIT KRAS
35 embryonal sarcoma 10.8 CTNNB1 KIT TP53
36 rete testis adenocarcinoma 10.8 AFP CEACAM5 KIT
37 ovarian cystadenocarcinoma 10.8 CEACAM5 HRAS KRAS
38 core binding factor acute myeloid leukemia 10.8 HRAS KIT KRAS
39 acinar cell carcinoma 10.8 AFP CTNNB1 TP53
40 lung benign neoplasm 10.8 EGFR HRAS KRAS TP53
41 mucinous adenocarcinoma 10.8 EGFR KRAS MLH1 TP53
42 soft tissue sarcoma 10.8 EGFR TP53 VEGFA
43 pancreatic cystadenocarcinoma 10.8 AFP CEACAM5 KRAS
44 esophagus sarcoma 10.8 KIT WWOX
45 biliary papillomatosis 10.8 CEACAM5 HRAS KRAS TP53
46 melanocytic nevus syndrome, congenital 10.8 HRAS MLH1 MSH2
47 ovary adenocarcinoma 10.8 CEACAM5 HRAS KRAS TP53
48 rete testis neoplasm 10.8 AFP CEACAM5 KIT
49 signet ring cell adenocarcinoma 10.8 CDH1 CTNNB1 TP53
50 brain ependymoma 10.8 EGFR TP53

Comorbidity relations with Gastrointestinal System Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Cholestasis Deficiency Anemia
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Gastrointestinal System Cancer:



Diseases related to Gastrointestinal System Cancer

Symptoms & Phenotypes for Gastrointestinal System Cancer

UMLS symptoms related to Gastrointestinal System Cancer:


signs and symptoms, digestive

GenomeRNAi Phenotypes related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.16 KRAS EGFR HRAS
2 Decreased viability GR00106-A-0 10.16 KRAS
3 Decreased viability GR00221-A-1 10.16 KIT KRAS AKT1 CDH1 EGFR HRAS
4 Decreased viability GR00221-A-2 10.16 KRAS AKT1 HRAS
5 Decreased viability GR00221-A-3 10.16 AKT1 HRAS
6 Decreased viability GR00221-A-4 10.16 AKT1 EGFR
7 Decreased viability GR00301-A 10.16 KIT KRAS MSH2 CDH1
8 Decreased viability GR00381-A-1 10.16 KRAS
9 Decreased cell migration GR00055-A-1 9.63 ADAM17 AKT1 CTNNB1 EGFR HRAS KRAS
10 Increased cell migration GR00055-A-3 9.02 ADAM17 CTNNB1 EGFR HRAS KRAS

MGI Mouse Phenotypes related to Gastrointestinal System Cancer:

43 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.5 ADAM17 AFP AKT1 AREG CCND1 CDH1
2 endocrine/exocrine gland MP:0005379 10.47 CTNNB1 EGFR HRAS KIT KRAS MLH1
3 cellular MP:0005384 10.46 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
4 digestive/alimentary MP:0005381 10.45 ADAM17 AREG CCND1 CDH1 CTNNB1 EGFR
5 mortality/aging MP:0010768 10.44 AREG CCND1 CDH1 CTNNB1 EGFR HRAS
6 cardiovascular system MP:0005385 10.4 ADAM17 AKT1 AREG CCND1 CDH1 CTNNB1
7 growth/size/body region MP:0005378 10.4 ADAM17 AKT1 AREG CCND1 CDH1 CTNNB1
8 immune system MP:0005387 10.4 CCND1 CDH1 CTNNB1 EGFR KIT KRAS
9 hematopoietic system MP:0005397 10.39 ADAM17 TLR9 TP53 VEGFA WWOX AKT1
10 integument MP:0010771 10.39 VEGFA ADAM17 AKT1 AREG CCND1 CDH1
11 neoplasm MP:0002006 10.32 HRAS KIT KRAS MLH1 MSH2 TP53
12 embryo MP:0005380 10.25 ADAM17 AKT1 CDH1 CTNNB1 EGFR KIT
13 nervous system MP:0003631 10.23 ADAM17 AKT1 CCND1 CTNNB1 EGFR HRAS
14 craniofacial MP:0005382 10.21 CCND1 CTNNB1 EGFR HRAS KIT KRAS
15 liver/biliary system MP:0005370 10.18 EGFR KIT KRAS TP53 VEGFA WWOX
16 normal MP:0002873 10.14 CTNNB1 EGFR HRAS KIT KRAS TP53
17 muscle MP:0005369 10.1 ADAM17 AKT1 CTNNB1 EGFR KIT KRAS
18 reproductive system MP:0005389 10.1 CDH1 CTNNB1 EGFR KIT KRAS MLH1
19 no phenotypic analysis MP:0003012 10.09 CDH1 CTNNB1 EGFR HRAS KIT KRAS
20 limbs/digits/tail MP:0005371 10.08 TP53 VEGFA ADAM17 CTNNB1 EGFR KIT
21 renal/urinary system MP:0005367 9.92 HRAS KIT KRAS TLR9 TP53 VEGFA
22 respiratory system MP:0005388 9.9 ADAM17 AKT1 CCND1 CTNNB1 EGFR HRAS
23 pigmentation MP:0001186 9.85 TP53 ADAM17 CTNNB1 EGFR KIT KRAS
24 skeleton MP:0005390 9.7 ADAM17 AKT1 CCND1 CTNNB1 EGFR HRAS
25 vision/eye MP:0005391 9.32 ADAM17 AREG CCND1 CTNNB1 EGFR KIT

Drugs & Therapeutics for Gastrointestinal System Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
GastroMARK 17 FERUMOXSIL Advanced Magnetics May 1996
2
Gleevec 17 45 IMATINIB MESYLATE Novartis May 2001
3
SecreFlo 17 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen April 2002
4
Stivarga 17 45 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
5
Sutent 17 45 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Gastrointestinal System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 306)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2
Celecoxib Approved, Investigational Phase 4,Phase 1 169590-42-5 2662
3 Parecoxib Approved Phase 4 198470-84-7
4
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
5
Fluorouracil Approved Phase 4,Phase 2,Phase 3,Phase 1 51-21-8 3385
6
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
7
Insulin Glargine Approved Phase 4 160337-95-1
8
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
9
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
11
Clarithromycin Approved Phase 4 81103-11-9 84029
12
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
13 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
15 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2
16 Analgesics, Opioid Phase 4
17 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1
18 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 1
19 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
20 Central Nervous System Depressants Phase 4,Phase 3
21 Cyclooxygenase 2 Inhibitors Phase 4,Phase 3,Phase 1
22 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 1
23 insulin Phase 4
24 Insulin, Globin Zinc Phase 4
25 Narcotics Phase 4
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
27 Vitamins Phase 4,Phase 2,Phase 1
28 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2
29 Anticoagulants Phase 4,Phase 1
30 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Neuromuscular Agents Phase 4
35 Neuromuscular Blocking Agents Phase 4
36 Neuromuscular Nondepolarizing Agents Phase 4
37 Hypoglycemic Agents Phase 4,Phase 1,Phase 2
38 Antacids Phase 4
39 Anti-Ulcer Agents Phase 4
40 Proton pump inhibitors Phase 4
41 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1
42 Vasodilator Agents Phase 4,Phase 1,Early Phase 1
43 Fibrinolytic Agents Phase 4
44 Cytochrome P-450 CYP3A Inhibitors Phase 4
45 Cytochrome P-450 Enzyme Inhibitors Phase 4
46 HIV Protease Inhibitors Phase 4,Phase 1,Phase 2
47
protease inhibitors Phase 4,Phase 1,Phase 2
48 Bufanolides Phase 4
49 Antihypertensive Agents Phase 4,Early Phase 1
50 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 359)

# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
3 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Unknown status NCT00790140 Phase 4
4 Nutritional Supplementation in Patients With no Signs of Malnutrition Unknown status NCT01894828 Phase 4
5 Medium Calorie Parenteral Nutrition on Patients With Gastrointestinal Cancer Undergoing Surgery Completed NCT01700062 Phase 4
6 The Laparotomy Study Completed NCT02140593 Phase 4 Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).;Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.
7 Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN) Completed NCT02216799 Phase 4 Glargine Insulin;Regular insulin
8 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
9 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
10 Comparison of Thromboembolic Events Between Enoxa® and Lovenox® in Patients Undergoing Digestive Cancer Recruiting NCT02444572 Phase 4 Enoxaparin 4000 UI
11 10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication Recruiting NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
12 Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma Not yet recruiting NCT02860429 Phase 4 Cinobufacini injection;chemotherapy
13 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
14 Aliskiren Study of Safety and Efficacy in Senior Hypertensives Withdrawn NCT01922141 Phase 4 Aliskiren;Amlodipine;Ramipril;Hydrochlorothiazide
15 Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer Unknown status NCT00209742 Phase 3 UFT;USEL/Leucovorin;Krestin
16 Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial Unknown status NCT00164892 Phase 3 Oral Vioxx (Rofecoxib)
17 Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial Unknown status NCT00165048 Phase 3 Vioxx (Rofecoxib)
18 Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers Unknown status NCT02161991 Phase 3 Aprepitant;placebo
19 Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Completed NCT02486198 Phase 3 placebo;GM;oxaliplatin-based chemotherapy
20 Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer Completed NCT02664974 Phase 3
21 Immunonutrition and Quality of Life of Cancer Patients Undergoing Oncological Treatment Completed NCT01423799 Phase 3
22 Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting Completed NCT00971399 Phase 3 ramosetron;ondansetron
23 Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery Completed NCT00798447 Phase 3 MLF 541;Lipofundin MCT
24 Efficacy of an Oral Formula in Prevention of Anti-cancer Therapy Side Effects Completed NCT00455247 Phase 3 Glutamine
25 Melatonin Versus Placebo and the Effect on Appetite in Advanced Cancer Patients Completed NCT00513357 Phase 3 Melatonin;Placebo
26 Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet Completed NCT01775449 Phase 3
27 Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma Completed NCT01829178 Phase 2, Phase 3 Silymarin;Placebo;chemotherapy
28 Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis Completed NCT00052962 Phase 3
29 Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Completed NCT01360853 Phase 3 ON 01910.Na;Gemcitabine;Gemcitabine
30 Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients Completed NCT01523431 Phase 2, Phase 3 Irinotecan Injection [Camptosar];5-fluorouracil;Leucovorin
31 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
32 Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
33 SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients Recruiting NCT03448549 Phase 3 Oxaliplatin;Tegafur,gimeracil and oteracil potassium;Xeloda
34 Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1) Recruiting NCT03199989 Phase 3 CapeOX(Capecitabine+Oxaliplatin)
35 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3
36 Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer Not yet recruiting NCT02956876 Phase 3 standard chemotherapy for colorectal cancer
37 Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index Not yet recruiting NCT02576080 Phase 3 Imatinib
38 IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer Suspended NCT00316745 Phase 3 Campto, Topotesin;TS-1;L-Plat;Isovorin;5-FU
39 Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With Gastrointestinal (GI) Cancer Undergoing Surgery Terminated NCT01023412 Phase 3
40 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
41 A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients Terminated NCT00254436 Phase 3 Procrit (epoetin alfa)
42 Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients Terminated NCT00516269 Phase 3 Methylphenidate;Placebo
43 Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo Terminated NCT00332280 Phase 2, Phase 3 AMT2003
44 Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer Unknown status NCT00209651 Phase 2 Campto, Topotesin;TS-1
45 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
46 The Effect of Bone Marrow-sparing Intensity-Modulated Radiotherapy to GI Cancer Unknown status NCT01863420 Phase 2
47 Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis Unknown status NCT00454519 Phase 2
48 Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer Unknown status NCT01980407 Phase 2 S-1, leucovorin, oxaliplatin
49 Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer Unknown status NCT00453323 Phase 2 Paclitaxel;Capecitabine
50 Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Tumors Unknown status NCT00691691 Phase 2

Search NIH Clinical Center for Gastrointestinal System Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: digestive system neoplasms

Genetic Tests for Gastrointestinal System Cancer

Genetic tests related to Gastrointestinal System Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Gastrointestinal Tract 28

Anatomical Context for Gastrointestinal System Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Gastrointestinal System Cancer:

18
Gastrointestinal Tract

MalaCards organs/tissues related to Gastrointestinal System Cancer:

38
Lung, Liver, Testes, Bone, Endothelial, Colon, Pancreas

Publications for Gastrointestinal System Cancer

Articles related to Gastrointestinal System Cancer:

# Title Authors Year
1
The effect of chemotherapy on nutritional status and weakness in geriatric gastrointestinal system cancer patients. ( 29429533 )
2018
2
The effect of intraoperative hypothermia upon blood transfusion needs and length of stay among gastrointestinal system cancer surgery. ( 28417506 )
2017
3
Perioperative immunonutrition ameliorates the postoperative immune depression in patients with gastrointestinal system cancer (prospective clinical study in 42 patients). ( 15587331 )
2004

Variations for Gastrointestinal System Cancer

Expression for Gastrointestinal System Cancer

Search GEO for disease gene expression data for Gastrointestinal System Cancer.

Pathways for Gastrointestinal System Cancer

Pathways related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.3 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
2
Show member pathways
14.15 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
3
Show member pathways
13.87 ADAM17 AKT1 AREG CCL15 CCND1 CDH1
4
Show member pathways
13.66 AKT1 AREG CCL15 CDH1 EGFR HRAS
5
Show member pathways
13.5 AKT1 AREG CCL15 CCND1 EGFR HRAS
6
Show member pathways
13.48 ADAM17 AKT1 CCND1 EGFR HRAS KIT
7
Show member pathways
13.42 AKT1 AREG CCL15 CDH1 CTNNB1 EGFR
8
Show member pathways
13.4 AKT1 AREG CDH1 CTNNB1 EGFR HRAS
9
Show member pathways
13.33 ADAM17 AKT1 AREG CCND1 EGFR HRAS
10
Show member pathways
13.18 AKT1 AREG EGFR HRAS KIT KRAS
11
Show member pathways
13.15 AKT1 AREG EGFR HRAS KIT KRAS
12
Show member pathways
13.14 AKT1 CTNNB1 EGFR HRAS KRAS VEGFA
13
Show member pathways
13.11 AKT1 CDH1 CTNNB1 HRAS KRAS TP53
14
Show member pathways
13.04 AKT1 CCND1 CTNNB1 EGFR HRAS KIT
15
Show member pathways
13.03 AKT1 HRAS KRAS MLH1 MSH2 TP53
16
Show member pathways
13.02 ADAM17 AKT1 EGFR HRAS KRAS VEGFA
17
Show member pathways
13.02 AKT1 CCND1 CTNNB1 EGFR HRAS KRAS
18
Show member pathways
12.98 AKT1 CTNNB1 HRAS KRAS TP53
19
Show member pathways
12.92 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
20 12.87 AKT1 EGFR HRAS KIT KRAS TP53
21
Show member pathways
12.86 AKT1 EGFR HRAS KIT KRAS TP53
22
Show member pathways
12.84 AKT1 CDH1 CTNNB1 HRAS KRAS TP53
23
Show member pathways
12.83 AKT1 CCND1 EGFR HRAS KRAS
24
Show member pathways
12.82 AKT1 CDH1 CTNNB1 EGFR HRAS KIT
25
Show member pathways
12.77 AKT1 EGFR HRAS KRAS TP53
26
Show member pathways
12.77 AKT1 CCND1 CTNNB1 EGFR HRAS KRAS
27
Show member pathways
12.74 ADAM17 AKT1 CCND1 CTNNB1 HRAS
28
Show member pathways
12.73 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
29
Show member pathways
12.69 AKT1 CTNNB1 EGFR HRAS KRAS MSH2
30
Show member pathways
12.67 AKT1 CCND1 EGFR HRAS KRAS TP53
31 12.66 CCND1 EGFR HRAS KRAS TP53 VEGFA
32
Show member pathways
12.66 AKT1 CCND1 CTNNB1 HRAS KRAS TP53
33 12.63 CCND1 MLH1 MSH2 TP53 WWOX
34
Show member pathways
12.62 AKT1 EGFR HRAS KRAS TP53
35
Show member pathways
12.57 AKT1 AREG CCND1 EGFR HRAS KRAS
36
Show member pathways
12.56 AKT1 CTNNB1 EGFR HRAS KRAS TP53
37 12.55 AKT1 CCND1 CDH1 CTNNB1 TP53
38
Show member pathways
12.55 CCND1 CTNNB1 EGFR HRAS KRAS
39
Show member pathways
12.54 AKT1 AREG CDH1 CTNNB1 EGFR HRAS
40
Show member pathways
12.53 AKT1 EGFR HRAS KIT KRAS
41
Show member pathways
12.53 AKT1 CTNNB1 HRAS KRAS VEGFA
42 12.53 AKT1 CCND1 CTNNB1 HRAS KRAS TP53
43
Show member pathways
12.5 CTNNB1 HRAS KIT KRAS TP53
44
Show member pathways
12.49 AKT1 EGFR HRAS KRAS VEGFA
45
Show member pathways
12.46 AKT1 CCND1 EGFR HRAS
46 12.46 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
47
Show member pathways
12.42 AKT1 CCND1 CTNNB1 HRAS
48
Show member pathways
12.42 AKT1 CCND1 EGFR HRAS
49
Show member pathways
12.41 AKT1 EGFR HRAS KRAS
50 12.39 CCND1 HRAS KRAS TP53

GO Terms for Gastrointestinal System Cancer

Cellular components related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.83 ADAM17 AFP AKT1 AREG CCND1 CDH1
2 basolateral plasma membrane GO:0016323 9.56 CEACAM5 CTNNB1 EGFR TLR9
3 cell-cell junction GO:0005911 9.46 ADAM17 AKT1 CTNNB1 KIT
4 catenin complex GO:0016342 9.4 CDH1 CTNNB1
5 flotillin complex GO:0016600 9.37 CDH1 CTNNB1
6 mismatch repair complex GO:0032300 8.62 MLH1 MSH2
7 membrane GO:0016020 10.22 ADAM17 AKT1 AREG CCND1 CDH1 CEACAM5

Biological processes related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.98 ADAM17 CCND1 CDH1 CTNNB1 TP53
2 negative regulation of gene expression GO:0010629 9.95 AKT1 CTNNB1 HRAS VEGFA
3 cell proliferation GO:0008283 9.93 AKT1 AREG CTNNB1 EGFR HRAS TP53
4 positive regulation of gene expression GO:0010628 9.91 CTNNB1 HRAS KIT KRAS TLR9 TP53
5 positive regulation of cell migration GO:0030335 9.88 ADAM17 EGFR HRAS KIT VEGFA
6 response to organic cyclic compound GO:0014070 9.87 AREG CCND1 EGFR TP53
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.85 AKT1 EGFR VEGFA
8 response to estradiol GO:0032355 9.85 AREG CCND1 CTNNB1 EGFR
9 positive regulation of cell growth GO:0030307 9.84 ADAM17 AKT1 EGFR
10 Ras protein signal transduction GO:0007265 9.82 HRAS KRAS TP53
11 positive regulation of MAPK cascade GO:0043410 9.81 CTNNB1 HRAS KIT TLR9
12 response to glucocorticoid GO:0051384 9.8 AREG CCND1 KRAS
13 positive regulation of epithelial cell proliferation GO:0050679 9.8 EGFR HRAS VEGFA
14 cellular response to growth factor stimulus GO:0071363 9.79 AKT1 CTNNB1 EGFR
15 positive regulation of DNA replication GO:0045740 9.77 AREG EGFR HRAS
16 ERBB2 signaling pathway GO:0038128 9.75 EGFR HRAS KRAS
17 cellular response to reactive oxygen species GO:0034614 9.73 AKT1 EGFR TP53
18 positive regulation of protein phosphorylation GO:0001934 9.7 ADAM17 AKT1 CCND1 EGFR HRAS KRAS
19 response to X-ray GO:0010165 9.67 CCND1 MSH2 TP53
20 response to UV-B GO:0010224 9.66 MSH2 TP53
21 positive regulation of cellular component movement GO:0051272 9.65 ADAM17 VEGFA
22 mitotic G1 DNA damage checkpoint GO:0031571 9.65 CCND1 TP53
23 positive regulation of MAP kinase activity GO:0043406 9.65 EGFR HRAS KIT KRAS VEGFA
24 positive regulation of isotype switching to IgG isotypes GO:0048304 9.64 MLH1 MSH2
25 response to isolation stress GO:0035900 9.63 HRAS KRAS
26 positive regulation of isotype switching to IgA isotypes GO:0048298 9.61 MLH1 MSH2
27 somatic recombination of immunoglobulin gene segments GO:0016447 9.61 MLH1 MSH2
28 mammary gland alveolus development GO:0060749 9.61 AREG CCND1 VEGFA
29 cellular response to indole-3-methanol GO:0071681 9.6 CDH1 CTNNB1
30 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.58 ADAM17 AKT1 EGFR
31 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.54 MLH1 MSH2
32 response to UV-A GO:0070141 9.5 AKT1 CCND1 EGFR
33 epidermal growth factor receptor signaling pathway GO:0007173 9.43 ADAM17 AKT1 AREG EGFR HRAS KRAS
34 positive regulation of cell proliferation GO:0008284 9.32 ADAM17 AKT1 AREG CCND1 CTNNB1 EGFR
35 positive regulation of transcription by RNA polymerase II GO:0045944 10.13 AKT1 CTNNB1 EGFR HRAS TLR9 TP53
36 cellular response to DNA damage stimulus GO:0006974 10.06 AKT1 CCND1 MLH1 MSH2 TP53

Molecular functions related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.93 AKT1 CEACAM5 KIT MSH2 TLR9 VEGFA
2 nucleotide binding GO:0000166 9.72 AKT1 EGFR HRAS KIT KRAS
3 protein C-terminus binding GO:0008022 9.67 CTNNB1 HRAS MSH2 TP53
4 protein phosphatase binding GO:0019903 9.61 CTNNB1 EGFR TP53
5 mismatched DNA binding GO:0030983 9.48 MLH1 MSH2
6 protein kinase binding GO:0019901 9.43 AKT1 CCND1 CTNNB1 EGFR MSH2 TP53
7 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.4 EGFR KIT
8 nitric-oxide synthase regulator activity GO:0030235 9.26 AKT1 EGFR
9 enzyme binding GO:0019899 9.17 AKT1 CCND1 CTNNB1 EGFR MSH2 TP53
10 guanine/thymine mispair binding GO:0032137 9.16 MLH1 MSH2

Sources for Gastrointestinal System Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....